Αποτελέσματα Αναζήτησης
21 Απρ 2023 · Of the pathogenic Klebsiella species, K. pneumoniae is the most prevalent and clinically important. Infections with K. pneumoniae are usually hospital-acquired and occur primarily in patients with impaired host defenses.
- Keri K Hall, Md, Ms
Clinical features, diagnosis, and treatment of Klebsiella...
- Tsay Rw, SIU Lk, Fung Cp, Chang Fy. Characteristics of Bacteremia Between Community-Acquired and Nosocomial Klebsiella Pneumoniae Infection: Risk Factor for Mortality and The Impact of Capsular Serotypes as a Herald for Community-Acquired Infection. Arch Intern Med 2002; 162:1021
Klebsiella pneumoniae liver abscesses, which were all...
- Keri K Hall, Md, Ms
The optimal approach to the treatment of infections caused by these multidrug-resistant strains remains undefined, and treatment decisions for an individual patient should be based on a number of organism- (for example, minimum inhibitory concentration) and patient-specific (for example, site of infection) factors.
16 Οκτ 2018 · Treatment of Klebsiella pneumonia has discrepant results. For patients with severe infections, a clinically prudent approach is the use of an initial short course (48-72 h) of combination therapy...
18 Αυγ 2022 · Summary. We retrospectively analyzed published data on the use and outcomes of antimicrobial therapy for K. pneumoniae infections. We discussed plazomicin, eravacycline, fosfomycin, tigecycline, and polymyxin as prevalent therapeutic options.
20 Ιουλ 2023 · Objectives: Describe the pathophysiology of Klebsiella. Identify the most common cause of hospital-acquired pneumonia in the United States. Recall patients most likely to get Klebsiella pneumonia. Review the evaluation and treatment of patients with Klebsiella pneumonia and the interprofessional team's role in managing patients with this condition.
27 Σεπ 2017 · The emergence of pandrug-resistant strains of K. pneumoniae highlights the critical need for consistent implementation of effective strategies for prevention of transmission and infection and for the development of new antimicrobials with activity against these emerging pathogens.
The aim of this review is to discuss the challenges in the management and treatment of patients with infections because of K. pneumoniae carbapenemase (KPC)-producing K. pneumoniae (KPC-KP) and provide an expert opinion. Table 1. Species distribution of Class A KPC. Modified by Miriagou and colleagues. 2. Open in a new tab.
